Key Points
- Insider Richard Ringler Fabian bought 10,000 Profound Medical shares at an average price of C$8.31, investing C$83,100 and establishing a 10,000-share position.
- Profound Medical reported a quarterly loss of C$0.37 per share on C$3.53 million in revenue, alongside a negative net margin of 170.92% and negative return on equity of 62.45%.
- Analyst sentiment remains favorable: Raymond James upgraded the stock to “strong buy,” while the broader analyst consensus is “Moderate Buy” with a C$8.23 target price.
-logo-1200x675.PNG?v=20210211152252)
Profound Medical Corp. (TSE:PRN - Get Free Report) insider Richard Ringler Fabian purchased 10,000 shares of the company's stock in a transaction that occurred on Thursday, September 17th. The stock was bought at an average price of C$8.31 per share, with a total value of C$83,100.00. Following the purchase, the insider owned 10,000 shares of the company's stock, valued at approximately C$83,100. The trade was a ∞ increase in their position.
Profound Medical Trading Up 0.6%
TSE PRN opened at C$8.23 on Friday. Profound Medical Corp. has a 12 month low of C$5.36 and a 12 month high of C$12.40. The company has a debt-to-equity ratio of 14.82, a current ratio of 6.46 and a quick ratio of 14.98. The company has a market capitalization of C$300.72 million, a price-to-earnings ratio of -8.31 and a beta of 1.06. The company's fifty day moving average price is C$9.65 and its two-hundred day moving average price is C$9.30.
Profound Medical (TSE:PRN - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share for the quarter. The company had revenue of C$3.53 million during the quarter. Profound Medical had a negative return on equity of 62.45% and a negative net margin of 170.92%. As a group, research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Raymond James Financial upgraded Profound Medical from a "moderate buy" rating to a "strong-buy" rating in a research note on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, nineteen have assigned a Moderate Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of C$8.23.
View Our Latest Stock Analysis on Profound Medical
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
